Reference standards are essential throughout biologic development, from assay validation to analytical characterization. Rather than serving as therapeutic candidates themselves, these reagents provide consistent benchmarks that allow researchers to evaluate new methods and compare experimental results with confidence.
A study published in Communications Medicine demonstrated this principle while validating a dendritic cell-based assay designed to predict the clinical immunogenicity of biologic therapeutics. Instead of relying on scarce commercial drug product, the researchers used research-grade biosimilars as standardized reference materials to evaluate assay performance.
The study highlights an emerging application for research-grade biosimilars: providing reproducible, well-characterized reference standards that support assay development and biologics research.
What Is a Research-Grade Biosimilar?
Research-grade biosimilars are recombinant antibodies designed to closely match the structure and biological activity of approved therapeutic antibodies for research use. Unlike clinical biosimilars intended for patient treatment, research-grade biosimilars are manufactured to support assay development, method validation, comparator studies, and preclinical research.
The Challenge: Validating Predictive Assays with Reliable Reference Standards
Predicting whether a biologic therapeutic will induce anti-drug antibodies (ADAs) remains an important challenge during drug development. Assays intended to evaluate immunogenicity must first be validated against molecules whose clinical behavior is already well understood.
Using commercial therapeutic drug product for assay development is often impractical because of limited availability, cost, and supply constraints. Researchers therefore require reference materials that provide consistent biological performance while remaining readily accessible for repeated experimental use.
Research-grade biosimilars offer a practical solution by providing standardized comparator molecules that can be incorporated into assay development workflows.
How Research-Grade Biosimilars Were Used
Researchers developed a dendritic cell-based assay designed to predict the clinical immunogenicity of biologic therapeutics.
To evaluate assay performance, they tested research-grade biosimilars representing several widely used therapeutic antibodies, including adalimumab, trastuzumab, and rituximab. Assay responses were then compared with published clinical immunogenicity data to determine whether the experimental measurements reflected known biological behavior.
Using standardized biosimilar reference materials allowed the investigators to evaluate assay performance across multiple therapeutics without relying on commercial clinical drug product.
Study Highlights
- Research-grade biosimilars served as standardized reference materials during assay validation.
- The assay demonstrated a strong correlation between experimental measurements and reported clinical immunogenicity.
- Multiple therapeutic antibodies were evaluated using consistent comparator molecules.
- The study demonstrates how research-grade biosimilars can support reproducible assay development and biologics research.
Why It Matters
Reliable reference standards are fundamental to reproducible biologics research. Whether validating a new assay, developing analytical methods, or comparing therapeutic candidates, researchers need comparator molecules that deliver consistent biological performance over time.
Research-grade biosimilars help meet this need by providing well-characterized recombinant antibodies that are readily available for laboratory research. Their consistency supports meaningful comparisons across experiments while reducing dependence on limited commercial therapeutic material.
As biologic development continues to expand, research-grade biosimilars are becoming increasingly valuable tools for assay development, analytical characterization, and translational research workflows.
Bio X Cell Reagents Used in This Study
- InVivoSIM™ Adalimumab Biosimilar (SIM0001)
- InVivoSIM™ Trastuzumab Biosimilar (SIM0005)
- InVivoSIM™ Rituximab Biosimilar (SIM0008)
These research-grade biosimilars are manufactured to provide consistent, well-characterized reference materials for assay development, comparator studies, and biologics research.
Citation
Jarvi NL, Balu-Iyer SV. A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics. Communications Medicine. 2023;3:174. (Confirm DOI before publication.)
Bio X Cell reagents were used in the cited study. This summary is provided for educational purposes and does not imply endorsement by the study authors. Humira (adalimumab), Herceptin (trastuzumab), and Rituxan (rituximab) are trademarks of their respective owners; the biosimilars are research-grade reagents and are not affiliated with or endorsed by the trademark holders.
Research Use Only